Cervical cancer is almost entirely preventable when precancerous cervical intraepithelial neoplasia (CIN) lesions are detected early through standardized cytologic and molecular screening.
Modern Co-Testing Protocol
- Liquid-Based Cytology (ThinPrep Pap Test): Significantly outperforms conventional Pap smears by capturing 100% of collected cervical cells in a liquid preservative vial, minimizing mucus, blood, and obscuring debris for superior cytopathological accuracy.
- High-Risk HPV DNA Genotyping: Molecular PCR amplification detecting 14 high-risk Human Papillomavirus genotypes, with specific identification of oncogenic genotypes 16 and 18, responsible for over 70% of cervical malignancies.
- Clinical Gynecological Examination: Gentle speculum inspection of the vaginal mucosa and cervix by experienced female gynecologists in a confidential, private clinical setting.
Recommended Screening Schedule
Women aged 21 to 65 are recommended to undergo periodic cervical cytology and HPV co-testing to ensure complete cervical wellness and peace of mind.
